Maarten W Taal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6733378/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of malnutrition on health-related quality of life in persons receiving dialysis: a prospective study. British Journal of Nutrition, 2022, 127, 1647-1655.	1.2	4
2	An Analysis of Frequency of Continuous Blood Pressure Variation and Haemodynamic Responses during Haemodialysis. Blood Purification, 2022, 51, 435-449.	0.9	4
3	Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity. World Journal of Nephrology, 2022, 11, 39-57.	0.8	5
4	Change in glomerular filtration rate over time in the Oxford Renal Cohort Study: observational study. British Journal of General Practice, 2022, 72, e261-e268.	0.7	6
5	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials, 2022, 23, 331	0.7	8
6	Repeatability of Contrast-Enhanced Ultrasound to Determine Renal Cortical Perfusion. Diagnostics, 2022, 12, 1293.	1.3	1
7	Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatology Advances in Practice, 2022, 6, .	0.3	2
8	Room for improvement: diagnosing and managing acute coronary syndromes in persons with reduced eGFR. Kidney International, 2022, 102, 20-22.	2.6	1
9	Adjustment and wellbeing among people with end-stage chronic kidney disease receiving in-centre haemodialysis during the COVID-19 pandemic. Journal of Kidney Care, 2022, 7, 70-79.	0.1	1
10	â€ĩl didn't have any option': experiences of people receiving in-centre haemodialysis during the COVID-19 pandemic. Journal of Kidney Care, 2022, 7, 112-119.	0.1	3
11	Simple, high-throughput measurement of gut-derived short-chain fatty acids in clinically relevant biofluids using gas chromatography-mass spectrometry. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, , .	1.3	0
12	An iterative run-to-run learning model to derive continuous brachial pressure estimates from arterial and venous lines during dialysis treatment. Biomedical Signal Processing and Control, 2021, 65, 102346.	3.5	2
13	A Feasibility Study of Non-Invasive Continuous Estimation of Brachial Pressure Derived From Arterial and Venous Lines During Dialysis. IEEE Journal of Translational Engineering in Health and Medicine, 2021, 9, 1-9.	2.2	10
14	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Clobal Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 99, 34-47.	2.6	195
15	The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 1345-1355.	1.4	10
16	Determinants of change in arterial stiffness over 5 years in early chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 281-288.	0.4	4
17	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. Health Technology Assessment, 2021, 25, 1-52.	1.3	19
18	Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney International Reports, 2021, 6, 2159-2170.	0.4	22

#	Article	IF	CITATIONS
19	OUP accepted manuscript. CKJ: Clinical Kidney Journal, 2021, 14, 1969-1976.	1.4	3
20	Quantitative assessment of renal structural and functional changes in chronic kidney disease using multi-parametric magnetic resonance imaging. Nephrology Dialysis Transplantation, 2020, 35, 955-964.	0.4	54
21	Validation of the European Renal Best Practice guideline algorithm for management of older patients with advanced chronic kidney disease: a commentary. Nephrology Dialysis Transplantation, 2020, 35, 908-911.	0.4	0
22	Coffee Consumption and Kidney Function: A Mendelian Randomization Study. American Journal of Kidney Diseases, 2020, 75, 753-761.	2.1	56
23	Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open, 2020, 10, e038423.	0.8	23
24	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	2.6	65
25	The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. PLoS Medicine, 2020, 17, e1003163.	3.9	19
26	A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression. Biomarker Insights, 2020, 15, 117727192097614.	1.0	1
27	Health-related quality of life, functional impairment and comorbidity in people with mild-to-moderate chronic kidney disease: a cross-sectional study. BMJ Open, 2020, 10, e040286.	0.8	15
28	Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: a prospective cohort study. Journal of Human Nutrition and Dietetics, 2020, 33, 852-861.	1.3	8
29	Nutritional status assessment: a neglected biomarker in persons with end-stage kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 547-554.	1.0	4
30	P1078IMPACT OF A MEDIUM CUT-OFF DIALYZER ON SKIN AUTOFLUORESCENCE IN HAEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
31	Application of the Lomb-Scargle Periodogram to InvestigateHeart Rate Variability during Haemodialysis. Journal of Healthcare Engineering, 2020, 2020, 1-18.	1.1	5
32	Dialysis-Induced Cardiovascular and Multiorgan Morbidity. Kidney International Reports, 2020, 5, 1856-1869.	0.4	42
33	Factors Associated With Change in Skin Autofluorescence, a Measure of Advanced Glycation End Products, in Persons Receiving Dialysis. Kidney International Reports, 2020, 5, 654-662.	0.4	8
34	The authors reply. Kidney International, 2020, 97, 616.	2.6	0
35	Helping people to live well with chronic kidney disease. British Journal of Hospital Medicine (London,) Tj ETQq1 1	0.784314	rgBT /Overlo

Biological variation of cardiac troponins in chronic kidney disease. Annals of Clinical Biochemistry, 2020, 57, 162-169.

0.8 4

#	Article	IF	CITATIONS
37	The authors reply. Kidney International, 2020, 97, 214-215.	2.6	Ο
38	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: AÂcohort study. PLoS Medicine, 2020, 17, e1003050.	3.9	4
39	Sodiumâ€glucose linked transporterâ€2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 1024-1034.	2.2	6
40	An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 3-15.	2.2	278
41	Impact of Dietetic Intervention on Skin Autofluorescence and Nutritional Status in Persons Receiving Dialysis: A Proof of Principle Study. , 2020, 30, 540-547.		6
42	Patients' and kidney care team's perspectives of treatment burden and capacity in older people with chronic kidney disease: a qualitative study. BMJ Open, 2020, 10, e042548.	0.8	13
43	Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Medicine, 2020, 17, e1003406.	3.9	99
44	Title is missing!. , 2020, 17, e1003163.		0
45	Title is missing!. , 2020, 17, e1003163.		0
46	Title is missing!. , 2020, 17, e1003163.		0
47	Title is missing!. , 2020, 17, e1003163.		0
48	Title is missing!. , 2020, 17, e1003163.		0
49	Title is missing!. , 2020, 17, e1003163.		Ο
50	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
51	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		Ο
52	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
53	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
54	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 17, e1003050.		0
56	Title is missing!. , 2020, 17, e1003050.		0
57	Title is missing!. , 2020, 17, e1003050.		0
58	Title is missing!. , 2020, 17, e1003050.		0
59	Title is missing!. , 2020, 17, e1003050.		0
60	Epidemiology and causes of chronic kidney disease. Medicine, 2019, 47, 562-566.	0.2	14
61	Considerable international variation exists in blood pressure control and antihypertensive prescriptionÂpatterns in chronic kidney disease. Kidney International, 2019, 96, 983-994.	2.6	51
62	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. Peritoneal Dialysis International, 2019, 39, 486-489.	1.1	12
63	CKD: A Call for an Age-Adapted Definition. Journal of the American Society of Nephrology: JASN, 2019, 30, 1785-1805.	3.0	198
64	SP541MEASURING PRESSURE WAVES IN DIALYSIS LINES TO DERIVE CONTINUOUS ARTERIAL BLOOD PRESSURE: PILOT WORK IN AN IN VITRO AND IN SILICO MODEL. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
65	FP630DEVELOPMENT OF AN IN VITRO SIMULATION MODEL TO INVESTIGATE HAEMODYNAMIC RESPONSES DURING HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
66	FP638FREQUENCY ANALYSIS REVEALS UNIQUE HAEMODYNAMIC RESPONSES TO HAEMODIALYSIS: BASELINE RESULTS FROM THE ITREND STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
67	Feasibility and effectiveness of preâ€emptive rehabilitation in persons approaching dialysis (PREHAB). Journal of Renal Care, 2019, 45, 9-19.	0.6	8
68	Sodium and water handling during hemodialysis: new pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease. Kidney International, 2019, 95, 296-309.	2.6	44
69	Biological variation of measured and estimated glomerular filtration rate in patients with chronicÂkidney disease. Kidney International, 2019, 96, 429-435.	2.6	63
70	Skin autofluorescence. Current Opinion in Nephrology and Hypertension, 2019, 28, 507-512.	1.0	14
71	Long-term outcomes after AKI—a major unmet clinical need. Kidney International, 2019, 95, 21-23.	2.6	20
72	The Association of Nutritional Factors and Skin Autofluorescence in Persons Receiving Hemodialysis. , 2019, 29, 149-155.		17

#	Article	IF	CITATIONS
73	Development of a haemodialysis patient safety index. Journal of Kidney Care, 2018, 3, 96-101.	0.1	1
74	SP265ASSESSMENT OF CHRONIC KIDNEY DISEASE USING MULTI-PARAMETRIC MRI: REPRODUCIBILITY, CORRELATION WITH HISTOLOGY AND PROGRESSION. Nephrology Dialysis Transplantation, 2018, 33, i433-i433.	0.4	0
75	Personalized medicine in nephrology. Current Opinion in Nephrology and Hypertension, 2018, 27, 395-397.	1.0	2
76	What every doctor needs to know about chronic kidney disease. British Journal of Hospital Medicine (London, England: 2005), 2018, 79, 438-443.	0.2	1
77	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.	1.6	145
78	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.4	91
79	What is the value of multidisciplinary care for chronic kidney disease?. PLoS Medicine, 2018, 15, e1002533.	3.9	4
80	FP313DETERMINANTS OF CHANGE IN ARTERIAL STIFFNESS OVER 5 YEARS IN EARLY CKD. Nephrology Dialysis Transplantation, 2018, 33, i136-i137.	0.4	0
81	SP284HOSPITAL ADMISSIONS IN PERSONS WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2018, 33, i438-i439.	0.4	0
82	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- Ill—rationale, trial design and baseline data. Nephrology Dialysis Transplantation, 2017, 32, gfw321.	0.4	24
83	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group. Nephrology Dialysis Transplantation, 2017, 32, 9-16.	0.4	120
84	Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open, 2017, 7, e016528.	0.8	25
85	Sodium MRI. Current Opinion in Nephrology and Hypertension, 2017, 26, 435-441.	1.0	14
86	Patients' Experiences After CKD Diagnosis: A Meta-ethnographic Study and Systematic Review. American Journal of Kidney Diseases, 2017, 70, 656-665.	2.1	35
87	Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis. Journal of the American Society of Nephrology: JASN, 2017, 28, 1269-1277.	3.0	117
88	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1671-1681.	1.4	12
89	SP240PRESCRIBING PATTERNS AT THE TIME OF AKI: OPPORTUNITIES TO IMPROVE CARE. Nephrology Dialysis Transplantation, 2017, 32, iii186-iii186.	0.4	0
90	Multiparametric Renal Magnetic Resonance Imaging: Validation, Interventions, and Alterations in Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 696.	1.3	96

#	Article	IF	CITATIONS
91	SP195EFFECT OF WEEKEND ADMISSION ON MORTALITY ASSOCIATED WITH SEVERE ACUTE KIDNEY INJURY IN ENGLAND: A PROPENSITY SCORE MATCHED, POPULATION-BASED STUDY. Nephrology Dialysis Transplantation, 2017, 32, iii169-iii169.	0.4	0
92	The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLoS Medicine, 2017, 14, e1002400.	3.9	51
93	Effect of weekend admission on mortality associated with severe acute kidney injury in England: A propensity score matched, population-based study. PLoS ONE, 2017, 12, e0186048.	1.1	4
94	MO032CKD REMISSION IN A PROSPECTIVE COHORT OF PEOPLE WITH CKD STAGE 3 RECRUITED FROM PRIMARY CARE. Nephrology Dialysis Transplantation, 2016, 31, i41-i41.	0.4	0
95	SP279CHANGE IN SKIN AUTOFLOURESCENCE OVER ONE YEAR PREDICTS MORTALITY AT FIVE YEARS IN A PROSPECTIVE COHORT OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2016, 31, i180-i181.	0.4	0
96	Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study. PLoS Medicine, 2016, 13, e1002128.	3.9	44
97	Regional Variation in Acute Kidney Injury Requiring Dialysis in the English National Health Service from 2000 to 2015 – A National Epidemiological Study. PLoS ONE, 2016, 11, e0162856.	1.1	7
98	TO025RISK FACTORS FOR CKD PROGRESSION AFTER ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2016, 31, i71-i72.	0.4	0
99	MP346VITAMIND DEFICIENCY AND ELEVATED PTH BUT NOT FGF-23 PREDICT ALL-CAUSE MORTALITY IN PEOPLE WITH CKD STAGE 3 IN PRIMARY CARE. Nephrology Dialysis Transplantation, 2016, 31, i454-i455.	0.4	0
100	Chronic kidney disease: towards a risk-based approach. Clinical Medicine, 2016, 16, s117-s120.	0.8	14
101	Where now for proteinuria testing in chronic kidney disease?: Good evidence can clarify a potentially confusing message. British Journal of General Practice, 2016, 66, 215-217.	0.7	3
102	Development of a trigger tool to detect harm during haemodialysis. Journal of Kidney Care, 2016, 1, 72-77.	0.1	4
103	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m ²). Nephrology Dialysis Transplantation, 2016, 31, ii1-ii66.	0.4	87
104	Multimorbidity in people with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 465-472.	1.0	62
105	UK Kidney Week 2016: innovation for better care. Journal of Kidney Care, 2016, 1, 78-80.	0.1	0
106	A simple care bundle for use in acute kidney injury: a propensity score-matched cohort study. Nephrology Dialysis Transplantation, 2016, 31, 1846-1854.	0.4	90
107	The epidemiology of hospitalised acute kidney injury not requiring dialysis in England from 1998 to 2013: retrospective analysis of hospital episode statistics. International Journal of Clinical Practice, 2016, 70, 330-339.	0.8	47
108	International Criteria for Acute Kidney Injury: Advantages and Remaining Challenges. PLoS Medicine, 2016, 13, e1002122.	3.9	23

#	Article	IF	CITATIONS
109	Reduction in sodium intake is independently associated with improved blood pressure control in people with chronic kidney disease in primary care. British Journal of Nutrition, 2015, 114, 936-942.	1.2	11
110	Skin autofluorescence: a risk marker for chronic kidney disease. Journal of Renal Nursing, 2015, 7, 214-221.	0.1	1
111	The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrology, 2015, 16, 193.	0.8	146
112	Chronic kidney disease in older people – diagnosis, aetiology and consequences. Current Opinion in Nephrology and Hypertension, 2015, 24, 475-479.	1.0	4
113	Long Term Outcomes after Acute Kidney Injury: Lessons from the ARID Study. Nephron, 2015, 131, 102-106.	0.9	12
114	Impact of Compliance with a Care Bundle on Acute Kidney Injury Outcomes: A Prospective Observational Study. PLoS ONE, 2015, 10, e0132279.	1.1	108
115	National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kidney International, 2015, 88, 1161-1169.	2.6	62
116	The kidneys find a voice in cardiovascular risk prediction. Nature Reviews Nephrology, 2015, 11, 510-512.	4.1	1
117	Epidemiology and causes of chronic kidney disease. Medicine, 2015, 43, 450-453.	0.2	21
118	FP351THE BURDEN AND SURVIVAL IMPLICATIONS OF COMORBIDITY IN PEOPLE WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2015, 30, iii185-iii186.	0.4	1
119	High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients. European Journal of Clinical Nutrition, 2015, 69, 786-790.	1.3	34
120	Exploration of Chronic Kidney Disease Prevalence Estimates Using New Measures of Kidney Function in the Health Survey for England. PLoS ONE, 2015, 10, e0118676.	1.1	27
121	The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease. PLoS ONE, 2015, 10, e0129980.	1.1	12
122	Assessment of Proteinuria in Patients with Chronic Kidney Disease Stage 3: Albuminuria and Non-Albumin Proteinuria. PLoS ONE, 2014, 9, e98261.	1.1	9
123	Development of a Formula for Estimation of Sodium Intake from Spot Urine in People with Chronic Kidney Disease. Nephron Clinical Practice, 2014, 128, 61-66.	2.3	18
124	Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1361-1368.	2.2	31
125	Progress in risk prediction for people with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 519-524.	1.0	5
126	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 169-173.	1.0	31

#	Article	IF	CITATIONS
127	Demographic Associations of High Estimated Sodium Intake and Frequency of Consumption of High-Sodium Foods in People With Chronic Kidney Disease Stage 3 in England. , 2014, 24, 236-242.		22
128	The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population. BMC Nephrology, 2014, 15, 13.	0.8	34
129	The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney International, 2014, 86, 407-413.	2.6	24
130	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 160	0.7	29
131	Socio-Economic Disparities in the Distribution of Cardiovascular Risk in Chronic Kidney Disease Stage 3. Nephron Clinical Practice, 2013, 122, 58-65.	2.3	8
132	Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Family Practice, 2013, 14, 88.	2.9	45
133	Determinants of survival in patients receiving dialysis in L ibya. Hemodialysis International, 2013, 17, 249-255.	0.4	6
134	Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrology Dialysis Transplantation, 2013, 28, 129-137.	0.4	148
135	Chronic kidney disease in general populations and primary care. Current Opinion in Nephrology and Hypertension, 2013, 22, 593-598.	1.0	6
136	Tissue Advanced Glycation End Product Deposition after Kidney Transplantation. Nephron Clinical Practice, 2013, 124, 54-59.	2.3	29
137	Determinants of Arterial Stiffness in Chronic Kidney Disease Stage 3. PLoS ONE, 2013, 8, e55444.	1.1	36
138	Natural History of Skeletal Muscle Mass Changes in Chronic Kidney Disease Stage 4 and 5 Patients: An Observational Study. PLoS ONE, 2013, 8, e65372.	1.1	55
139	Screening for Chronic Kidney Disease: Preventing Harm or Harming the Healthy?. PLoS Medicine, 2012, 9, e1001345.	3.9	11
140	Chronic kidney disease 10 years on. Current Opinion in Nephrology and Hypertension, 2012, 21, 607-611.	1.0	5
141	Hemoglobin Variability with Epoetin Beta and Continuous Erythropoietin Receptor Activator in Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2012, 32, 177-182.	1.1	18
142	Vascular Access in Patients Receiving Hemodialysis in Libya. Journal of Vascular Access, 2012, 13, 468-474.	0.5	2
143	Treatment needs and diagnosis awareness in primary care patients with chronic kidney disease. British Journal of General Practice, 2012, 62, e227-e232.	0.7	57
144	Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases, 2012, 12, 265.	1.3	63

#	Article	IF	CITATIONS
145	Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya. BMC Nephrology, 2012, 13, 33.	0.8	23
146	Anthropomorphic Measurements That Include Central Fat Distribution Are More Closely Related with Key Risk Factors than BMI in CKD Stage 3. PLoS ONE, 2012, 7, e34699.	1.1	62
147	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
148	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009–2012). Nephron Clinical Practice, 2011, 118, c27-c70.	2.3	23
149	Provision and quality of dialysis services in <scp>L</scp> ibya. Hemodialysis International, 2011, 15, 444-452.	0.4	7
150	Epidemiology and causes of chronic kidney disease. Medicine, 2011, 39, 402-406.	0.2	23
151	An unusual case of severe high anion gap metabolic acidosis. CKJ: Clinical Kidney Journal, 2011, 4, 90-92.	1.4	2
152	Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice, 2011, 118, c71-c100.	2.3	23
153	Risk Profile in Chronic Kidney Disease Stage 3: Older versus Younger Patients. Nephron Clinical Practice, 2011, 119, c269-c276.	2.3	23
154	Use of Online Conductivity Monitoring to Study Sodium Mass Balance in Chronic Haemodialysis Patients: Prospects for Treatment Individualisation. Kidney and Blood Pressure Research, 2011, 34, 439-446.	0.9	18
155	Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2356-2363.	2.2	94
156	Predicting Renal Risk in the General Population. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1523-1525.	2.2	12
157	Risk Factors and Chronic Kidney Disease. , 2011, , 758-781.		4
158	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. , 2011, , 1918-1971.		5
159	Tissue-Advanced Glycation End Product Concentration in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 51-55.	2.2	53
160	Renal infarction in patients presenting with suspected renal colic. CKJ: Clinical Kidney Journal, 2009, 2, 362-364.	1.4	3
161	A Meta-analysis of Hemodialysis Catheter Locking Solutions in the Prevention of Catheter-Related Infection. American Journal of Kidney Diseases, 2008, 51, 233-241.	2.1	169
162	Renal risk scores: Progress and prospects. Kidney International, 2008, 73, 1216-1219.	2.6	91

#	Article	IF	CITATIONS
163	How to measure proteinuria?. Current Opinion in Nephrology and Hypertension, 2008, 17, 600-603.	1.0	32
164	Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1241-1248.	2.2	267
165	Markers of Arterial Stiffness Are Risk Factors for Progression to End-Stage Renal Disease among Patients with Chronic Kidney Disease Stages 4 and 5. Nephron Clinical Practice, 2007, 107, c177-c181.	2.3	79
166	Defining renal risk. Current Opinion in Nephrology and Hypertension, 2007, 16, 554-556.	1.0	11
167	Comparison of Progressive Conductivity Reduction with Diacontrol and Standard Dialysis. ASAIO Journal, 2007, 53, 194-200.	0.9	23
168	Automated Peritoneal Dialysis Has Significant Effects on Systemic Hemodynamics. Peritoneal Dialysis International, 2006, 26, 328-335.	1.1	34
169	Effects of Acetate-Free Double-Chamber Hemodiafiltration and Standard Dialysis on Systemic Hemodynamics and Troponin T Levels. ASAIO Journal, 2006, 52, 62-69.	0.9	41
170	Preventing catheter related infections in haemodialysis patients. Current Opinion in Nephrology and Hypertension, 2006, 15, 599-602.	1.0	7
171	Continuous online monitoring of ionic dialysance allows modification of delivered hemodialysis treatment time. Hemodialysis International, 2006, 10, 346-350.	0.4	7
172	Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney International, 2006, 70, 1694-1705.	2.6	221
173	Vascular calcification and cardiovascular function in chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 707-714.	0.4	189
174	Automated peritoneal dialysis has significant effects on systemic hemodynamics. Peritoneal Dialysis International, 2006, 26, 328-35.	1.1	15
175	Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrology Dialysis Transplantation, 2005, 20, 1848-1853.	0.4	43
176	An unusual case of renovascular hypertension–renal artery stenosis of a pelvic kidney with aberrant blood supply. Nephrology Dialysis Transplantation, 2005, 20, 2861-2863.	0.4	4
177	Prospective study of gentamicin locking of tunnelled dialysis catheters: The effect on infection rates and CRP. Kidney International, 2005, 67, 378.	2.6	8
178	Online Conductivity Monitoring: Validation and Usefulness in a Clinical Trial of Reduced Dialysate Conductivity. ASAIO Journal, 2005, 51, 70-76.	0.9	58
179	Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrology Dialysis Transplantation, 2005, 20, 1140-1147.	0.4	118
180	Length of interdialytic interval influences serum calcium and phosphorus concentrations. Nephrology Dialysis Transplantation, 2005, 20, 1643-1646.	0.4	32

#	Article	IF	CITATIONS
181	Online measurement of haemoglobin concentration. Nephrology Dialysis Transplantation, 2005, 20, 1951-1955.	0.4	9
182	Analysis of factors associated with variability in haemodialysis adequacy. Nephrology Dialysis Transplantation, 2004, 19, 406-412.	0.4	38
183	Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. Nephrology Dialysis Transplantation, 2004, 19, 1542-1545.	0.4	82
184	Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney International, 2004, 66, 801-805.	2.6	134
185	Slowing the Progression of Adult Chronic Kidney Disease. Drugs, 2004, 64, 2273-2289.	4.9	27
186	Imaging and assessment of vascular calcification in chronic kidney disease patients. Current Opinion in Nephrology and Hypertension, 2004, 13, 637-640.	1.0	4
187	Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney International, 2003, 63, 1116-1120.	2.6	65
188	Adherence of tunnelled haemodialysis catheter to superior vena caval stent: successful percutaneous removal. Nephrology Dialysis Transplantation, 2003, 18, 432-433.	0.4	10
189	Assessment of haemodialysis adequacy by ionic dialysance: intra-patient variability of delivered treatment. Nephrology Dialysis Transplantation, 2003, 18, 559-563.	0.4	44
190	Proteinuria: new information from an old friend. Current Opinion in Nephrology and Hypertension, 2003, 12, 615-617.	1.0	0
191	Combination ACEI and ARB therapy: additional benefit in renoprotection?. Current Opinion in Nephrology and Hypertension, 2002, 11, 377-381.	1.0	60
192	Activation of proinflammatory mediators in heart transplants from brain-dead donors: evidence from a model of chronic rat cardiac allograft rejection. Transplantation Proceedings, 2002, 34, 2359-2360.	0.3	17
193	Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 519-527.	3.0	47
194	How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease. , 2002, , 1-8.		0
195	Mechanisms underlying renoprotection during renin-angiotensin system blockade. American Journal of Physiology - Renal Physiology, 2001, 280, F343-F355.	1.3	50
196	Evolving strategies for renoprotection: non-diabetic chronic renal disease. Current Opinion in Nephrology and Hypertension, 2001, 10, 523-531.	1.0	13
197	Pathogenesis of diabetic nephropathy: focus on transforming growth factor-Î ² and connective tissue growth factor. Current Opinion in Nephrology and Hypertension, 2001, 10, 727-738.	1.0	49
198	Achieving maximal renal protection in nondiabetic chronic renal disease. American Journal of Kidney Diseases, 2001, 38, 1365-1371.	2.1	13

#	Article	IF	CITATIONS
199	Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone. Journal of the American Society of Nephrology: JASN, 2001, 12, 2051-2059.	3.0	86
200	Activation of the Heart by Donor Brain Death Accelerates Acute Rejection After Transplantation. Circulation, 2000, 102, 2426-2433.	1.6	182
201	Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression. Current Opinion in Nephrology and Hypertension, 2000, 9, 323-331.	1.0	36
202	Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant?. Current Opinion in Nephrology and Hypertension, 2000, 9, 651-657.	1.0	14
203	Multi-hit nature of chronic renal disease. Current Opinion in Nephrology and Hypertension, 2000, 9, 85-97.	1.0	104
204	Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney International, 2000, 57, 1803-1817.	2.6	390
205	Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney International, 2000, 58, 1664-1676.	2.6	108
206	Diagnostics and techniques. Current Opinion in Nephrology and Hypertension, 2000, 9, 649-650.	1.0	0
207	IHG-2, a Mesangial Cell Gene Induced by High Glucose, Is Human gremlin. Journal of Biological Chemistry, 2000, 275, 9901-9904.	1.6	126
208	Risk factors for reduced bone density in haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 1922-1928.	0.4	167
209	Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 1917-1921.	0.4	41
210	Renal mass: An important determinant of late allograft outcome. Transplantation Reviews, 1998, 12, 74-84.	1.2	25
211	The Impact of Donor Brain Death on Graft Integrity after Transplantation. Graft: Organ and Cell Transplantation, 0, 5, 164-166.	0.0	0